PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33442459-4 2020 CASE SUMMARY: We present the cases of six liver transplant recipients who had previous treatment failure with sofosbuvir-based DAA therapy prior to transplantation and who then received SOF/VEL/VOX after transplant. Sofosbuvir 110-120 small integral membrane protein 1 (Vel blood group) Homo sapiens 186-197 34957030-3 2021 Sofosbuvir/velpatasvir (SOF/VEL) and sofosbuvir/ledipasvir (SOF/LDV) regimens became reimbursable in China in 2020. Sofosbuvir 0-10 small integral membrane protein 1 (Vel blood group) Homo sapiens 24-31 32656649-3 2020 Here, we report three patients with HCV NS5A-P32del infection who were treated with sofosbuvir, velpatasvir plus ribavirin (SOF/VEL + RBV) in a real-world setting. Sofosbuvir 84-94 small integral membrane protein 1 (Vel blood group) Homo sapiens 128-131 32189931-1 2020 Background: Our data is one of the earliest study from the Indian subcontinent on Velpatasvir/Sofosbuvir (VEL/SOF) combination in chronic hepatitis C (CHC). Sofosbuvir 94-104 small integral membrane protein 1 (Vel blood group) Homo sapiens 106-113 32154326-1 2020 Background: Clinical trials show high efficacy of sofosbuvir/velpatasvir (SOF/VEL), but there are limited data from "real-world" settings. Sofosbuvir 50-60 small integral membrane protein 1 (Vel blood group) Homo sapiens 78-81 31433303-1 2019 BACKGROUND AND AIMS: Sofosbuvir/Velpatasivr/Voxilaprevir (SOF/VEL/VOX) is approved for retreatment of hepatitis C (HCV) patients with a previous failure to direct-acting antivirals (DAA), however real-life data are limited. Sofosbuvir 21-31 small integral membrane protein 1 (Vel blood group) Homo sapiens 62-65 31012179-1 2019 Sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) provides a needed hepatitis C virus (HCV) antiviral option for direct-acting antiviral (DAA)-experienced patients. Sofosbuvir 0-10 small integral membrane protein 1 (Vel blood group) Homo sapiens 41-44 31203153-19 2019 LAY SUMMARY: Treatment with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) for 12 weeks is the current recommendation for the 5% of patients infected with HCV who do not achieve eradication of the virus under treatment with direct-acting antivirals. Sofosbuvir 28-38 small integral membrane protein 1 (Vel blood group) Homo sapiens 65-76 29886154-1 2018 BACKGROUND & AIMS: Sofosbuvir, an NS5B inhibitor, combined with velpatasvir, an NS5A inhibitor (SOF/VEL), produces high sustained virologic response rates 12 weeks after treatment (SVR12) in patients with genotype 1-6 HCV infection, and has no anticipated clinically relevant drug-drug interactions with immunosuppressants. Sofosbuvir 23-33 small integral membrane protein 1 (Vel blood group) Homo sapiens 104-107 30098373-14 2018 LAY SUMMARY: In phase III studies, 12 weeks of treatment with the combination of sofosbuvir, velpatasvir and voxilaprevir (SOF/VEL/VOX) cured 97% of patients with hepatitis C virus who failed prior treatment with direct-acting antiviral drugs. Sofosbuvir 81-91 small integral membrane protein 1 (Vel blood group) Homo sapiens 127-130 30556034-2 2018 Sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) is currently approved for treatment of HCV in patients with prior treatment with DAAs. Sofosbuvir 0-10 small integral membrane protein 1 (Vel blood group) Homo sapiens 41-44 30288771-4 2018 RESULTS: SOF/VEL/VOX is positioned as a salvage regimen for patients previously treated with NS5A inhibitors and for genotype 1a- and 3-infected patients who had failed other sofosbuvir-containing regimens. Sofosbuvir 175-185 small integral membrane protein 1 (Vel blood group) Homo sapiens 9-20 29665069-1 2018 BACKGROUND: Data are limited regarding the effectiveness and safety of generic velpatasvir plus sofosbuvir (VEL/SOF) for hepatitis C virus (HCV) in patients with or without human immunodeficiency virus (HIV) coinfection. Sofosbuvir 96-106 small integral membrane protein 1 (Vel blood group) Homo sapiens 108-111